Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
The aetiology of DCM is poorly understood and appears to be very heterogeneous. Viral infections, autoimmune disease and toxic substances are believed to be causative in a proportion of DCM although definitive proof has often been difficult to obtain. Recent studies have suggested that DCM has a familial appearance in 30-50% of cases implying that genetic factors may play an important role in disease development in a substantial proportion of patients (3). More than 40 disease genes have been identified encoding proteins involved in a variety of cell functions ranging from force generation within the sarcomere to regulation of ion-channels. Most affected families present with a “pure” cardiac phenotype and in these families autosomal dominant transmission is most frequent followed by recessive and X-linked inheritance. Recent studies have suggested a particular severe disease expression in DCM patients carrying mutations in the gene for lamin A/C, encoding a nuclear enveloped protein, expressed in most human cells.
In the paper of the month the authors report the frequency of desmosomal protein gene mutations in a cohort of 100 unrelated DCM probands. Previous studies have identified mutations in the same genes in patients with arrythmogenic right ventricle cardiomyopathy, (ARVC), which is a condition characterised by dilatation of the right ventricle, development of myocardial aneurysms, ventricular arrhythmias, and fibro-fatty replacement of myocytes. Since some ARVC patients present with biventricular disease the authors hypothesized that desmosomal gene mutations may also be associated with DCM (4). All patients in the current study fulfilled diagnostic criteria of DCM without any signs of ARVC. Five mutations were identified in 5 probands in addition to sequence variants of uncertain pathogenic significance in an additional
13 probands. Relatives were available for clinical and genetic investigations in 2 families in which a total of 6 mutation carriers presented with a heterogeneous disease expression.
This paper is the first to report that desmosomal gene mutations are responsible for a significant proportion of DCM and not only restricted to be the causative agent in ARVC. The results illustrate that genetic investigations have provided important knowledge about the aetiology of hereditary cardiac conditions and underscores that mutations in the same gene may lead to a variety of different cardiac conditions and manifestations. In addition to the disease associated mutations reported a fairly large number of sequence variations within the genes investigated were identified. However due to the limited number of affected individuals available for the study it was not possible to establish if these variations were disease associated which illustrates the difficulties in how to interpret the results of the genetic investigations. The authors rightfully argue that a conservative approach is preferable and that additional affected individuals carrying identical mutations should be available before sequence variants should be used for genetic counselling.
Circ Cardiovasc Genet. 2010;3:314-22
Mestroni,L., Maisch,B., McKenna,W.J., Schwartz,K., Charron,P., Rocco,C., Tesson,F., Richter,A., Wilke,A., and Komajda,M. 1999. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy. Eur.Heart J. 20:93-102.
Towbin,J.A. and Bowles,N.E. 2000. The failing heart. Nature 415:227-233.
Mahon N.G., Murphy R.T., MacRae C.A., Caforio A.L., Elliott P.M., McKenna W.J. 2005. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med. 19:108-15.
Norman M., Simpson M., Mogensen J., Shaw A., Hughes S., Syrris P., Chowdhry S.S., Rowland E., Crosby A., McKenna W.J. 2005. A Novel Mutation in Desmoplakin causes Arrythmogenic Left Ventricular Cardiomyopathy. Circulation:112, 636-42.
Choi,M., Scholl,U.I., Ji,W., Liu,T., Tikhonova,I.R., Zumbo,P., Nayir,A., Bakkaloglu,A., Ozen,S., Sanjad,S. et al. 2009. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc.Natl.Acad.Sci.U.S.A. 106:19096-19101.
Ng,S.B., Buckingham,K.J., Lee,C., Bigham,A.W., Tabor,H.K., Dent,K.M., Huff,C.D., Shannon,P.T., Jabs,E.W., Nickerson,D.A. et al. 2010. Exome sequencing identifies the cause of a mendelian disorder. Nat.Genet.2010. 42:30-35.
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 BIOT
06903Sophia Antipolis, FR
© 2017 European Society of Cardiology. All rights reserved